• Targeted Anti-D, The First Irish Perspective

      McCormick, C.A; Mulvany, L; De Tavernier, M.C (Irish Medical Journal, 2019-04)
      The use of anti-D to prevent haemolytic disease of the new-born can be regarded as one of the greatest success stories of modern medicine. Rhesus antibodies cause significant harm to rhesus positive foetuses in utero including anaemia, jaundice, hydrops fetalis and stillbirth. Deaths due to haemolytic disease of the new born have fallen dramatically. In the UK 1 in 2180 babies in 1953 died due to Rhesus haemolytic disease. 37 years later, in 1990, this figure had dropped to 1 in 62,500 1. Recent initiatives including the routine administration of anti-D at 28-32 weeks gestation have further reduced the incidence of sensitisation2.